Navamedic ASA (OSL:NAVA)

Market Cap	415.08M
Revenue (ttm)	542.59M
Net Income (ttm)	-10.95M
Shares Out	17.66M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	28.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,938
Average Volume	14,632
Open	23.40
Previous Close	23.60
Day's Range	23.00 - 24.00
52-Week Range	17.10 - 33.50
Beta	0.38
RSI	52.96
Earnings Date	Aug 14, 2025

About Accolade

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.